Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 270

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 270
---
 the quorum requirement but will not count as a vote cast at the Special Meeting. A broker non-vote will neither be counted towards the quorum requirement (as we believe the ParentCo Charter Proposal will be considered as non-discretionary) nor count as a vote cast in the Special Meeting. The stockholder votes regarding the ParentCo Charter Proposal are advisory votes and are not binding on us or our Board.

#### Recommendation of the Iris Board

### THE IRIS BOARD UNANIMOUSLY RECOMMENDS THAT
<div align='center'>IRIS STOCKHOLDERS VOTE “FOR” THE PARENTCO CHARTER PROPOSAL.

132</div>

TABLE OF CONTENTS

#### PROPOSAL NO. 5 — THE ADVISORY CHARTER PROPOSALS
In connection with the Business Combination, Iris is asking its stockholders to vote upon, on a non-binding advisory basis, proposals to approve certain governance provisions contained in the Proposed ParentCo Certificate of Incorporation. This separate vote is not otherwise required by Delaware law separate and apart from the Charter Proposal. Pursuant to SEC guidance, Iris is submitting these provisions to its stockholders separately for approval, allowing stockholders the opportunity to present their separate views on important governance provisions. However, the stockholder votes regarding these proposals are advisory votes, and are not binding on Iris or the Iris Board (separate and apart from the Charter Proposal). In the judgment of the special committee and the Iris Board, these provisions are necessary to adequately address the needs of the Combined Company. Furthermore, the Business Combination is not conditioned on the separate approval of the Advisory Charter Proposals.

Iris stockholders will be asked to approve, on a non-binding advisory basis, the following material differences between the Proposed ParentCo Certificate of Incorporation and the Iris Certificate of Incorporation, which are being presented as six separate sub-proposals (the “Advisory Charter Proposals”):

(1)

Advisory Charter Proposal A — to amend the name of the public entity to “Liminatus Pharma, Inc.” from “Iris Acquisition Corp”;

(2)

Advisory Charter Proposal B — to authorize the issuance of up to 500,000,000 shares of common stock, and up to 1,000,000 shares of “blank check” preferred stock, the rights, preferences and privileges of which may be designated from time to time by Liminatus’s board of directors;

(3)

Advisory Charter Proposal C —